Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0242379 (lung cancer)
 71,905 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Small cell carcinoma (SmC) of the esophagus is rare, and is sometimes impossible to detect by macroscopic inspection using an endoscope or histological examination of biopsied specimens. A 73-year-old man received F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) to evaluate the response to radiofrequency thermal ablation therapy for lung cancer. FDG-PET showed abnormal accumulation in the posterior mediastinum. Endoscopy disclosed ulcerous lesions with marginal elevation in the middle segment of the esophagus, but the biopsy specimen taken concurrently was not malignant histologically. FDG-PET, performed two months later, revealed abnormal accumulation in the suspect area, and the extent of accumulation was wider than previously. Histological examination of the specimen biopsied during the endoscopy led to a diagnosis of SmC. FDG-PET thus proved useful in the early detection of SmC.
 ...
PMID:A case of small cell carcinoma of the esophagus detected incidentally by FDG-PET. 1568 52

Fluorodeoxyglucose-PET imaging has secured an important role in the assessment and management of a multitude of pulmonary disorders, including solitary pulmonary nodules, lung cancer, and pleural diseases. While conventional imaging modalities such as chest radiography and CT are considered essential in these settings, FDG-PET can provide new information and complement structural imaging techniques in the evaluation of such disorders. In this review, the authors present a growing body of evidence that demonstrates and supports the utility of FDG-PET in the differentiation of benign and malignant pulmonary nodules, the assessment of lung cancer in various stages of disease, and the characterization of pleural diseases. In addition, new developments--such as prospects for potential utility of novel radiotracers and delayed imaging--that can further refine the role of FDG scans in the work-up of lung nodules and cancer and forecast the future place of PET in these common modalities are discussed.
 ...
PMID:Fluorodeoxyglucose-PET in characterizing solitary pulmonary nodules, assessing pleural diseases, and the initial staging, restaging, therapy planning, and monitoring response of lung cancer. 1569 44

We reviewed our initial institutional experience with the use of stereotactic hypofractionated radiation therapy (SFRT) in patients with stage I non-small cell lung cancer (NSCLC). Thirty patients with inoperable stage I non-small cell lung cancer due to a severe chronic obstructive pulmonary disease (COPD) and/or chronic heart disease (Eastern Cooperative Oncology Group (ECOG) performance status of 0-2) were treated between December 2000 and October 2003 with SFRT in curative intent. Infiltration of locoregional lymph nodes and distant metastases were ruled out by computerized tomography (CT) scan of the brain, thorax, and abdomen, and by whole body FDG-positron emission tomography scan in all patients. Total RT doses ranged from 24.0 to 37.5 Gy, given in 3-5 fractions to the 60% isodose encompassing the planning target volume. Immobilization was carried out by a vacuum couch and a low-pressure foil. The clinical target volume was the tumor as it appeared in lung windowing on lung CT scan. Organ movements (caused by breathing; range, 6-22 mm) and reproducibility of patient positioning in the couch (range, 3-12 mm) were calculated by sequential CT and orthogonal films. The individual values were taken into account as a safety margin for the definition of the planning target volume (PTV). The median follow-up of living patients is 18 months (range, 6-38 months). As maximum response, there were 10 (33%) complete responses (CRs) and 14 (47%) partial responses (PRs), resulting in a total response rate of 80%. Stable disease was observed in 6 (20%) patients, while no patient experienced progressive disease. During follow-up, 2 (7%) local recurrences were observed (after 17 and 18 months, respectively). Of 5 (17%) patients who developed distant metastasis, 1 patient developed it in liver (3 months), another one in brain (6 months), and another one in the lung (36 months), while 2 patients developed it in mediastinal lymph nodes (after 8, and 11 months, respectively) only. Of 9 (30%) patients who have died, only 3 (10%) died of cancer, while 6 (20%) died of cancer-unrelated or unknown causes. Acute side effects were mild and affected 9 (33%) patients during the RT course (fatigue being the most frequent one in 6 patients). There were 22 acute events occurring in 19 (63%) patients during the first 3 months post-SFRT, the most frequent one being pneumonitis observed in 14 (46%) patients. However, there was only one (3%) grade 3 acute toxicity and no patient experienced greater than grade 3 toxicity during this study. One (3%) patient experienced rib fracture as the late event. SFRT is a feasible and safe treatment method in inoperable patients with stage I NSCLC having reduced lung capacity. Longer follow-up is necessary to get robust data on late toxicity as well as survival.
Lung Cancer 2005 Apr
PMID:Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer. 1577 77

A 60-year-old male in a high-risk group for lung cancer, who also had positive sputum cytology, underwent examination by chest plain radiography, chest computed tomography (CT) and bronchofiberscopy. However, initially no abnormal findings were detected with these diagnostic modalities. Furthermore, thin-section spiral chest CT disclosed only a slight thickness of the right side of the tracheal wall, while consequent re-examination by bronchofiberscopy revealed only a light ulcerative lesion in the same area. However, the existence of a primary tumor was not confirmed using these modalities. Therefore, FDG-PET (positron emission tomography with fluorodeoxyglucose) was performed and demonstrated accumulation corresponding to the anterior mediastinum, although the exact location of the tumor was unclear by FDG-PET alone. Therefore, FDG-PET/CT image fusion was performed and resulted in the detection of a tracheal carcinoma on the outside of the right side of the tracheal wall. The patient then underwent tracheal sleeve resection including the tumor and tracheoplasty accompanied with wrapping using the flap of the thymus right lobe. To the best of our knowledge, this is the first reported case of tracheal carcinoma detected by FDG-PET/CT image fusion with consequent radical resection.
 ...
PMID:Occult cancer detected by positron emission tomography/computed tomography image fusion. 1581 12

A 69-year-old man with a history of lung cancer was referred for FDG whole body positron emission tomography (PET) with computed tomography (CT) fusion. Three days before the study, the patient was involved in a motor vehicle accident (MVA). In addition to hypermetabolic lesions representing metastatic lung cancer, PET scan showed marked anterior and lateral abdominal muscle uptake. Multiple focal abnormalities were seen on the PET scan that corresponded to multiple rib fractures on the CT scan that were secondary to the MVA. When the patient was interviewed, he stated that he had thoracic wall pain that prevented him from breathing properly. This case illustrates an unusual pattern of increased anterior and lateral abdominal muscle uptake as a result of pain while breathing.
 ...
PMID:Abdominal muscle uptake on FDG PET secondary to multiple rib fractures and use of accessory muscles of respiration. 1582 5

Lung cancer is nowadays one of the most common malignancies and the leading cause of cancer mortality worldwide. Its early diagnosis and treatment is therefore the target of extensive research. Although radiologic imaging methods, especially CT, are the most widely used, they have well known constraints, including solitary pulmonary nodule characterisation, mediastinal lymph node staging, characterisation of the remaining tissue after chemo- or radiotherapy and early diagnosis of relapse. The main reason for these drawbacks is that radiologic methods primarily rely upon morphologic and anatomic criteria, which usually have little relevance to the biological status of a pulmonary lesion. The radiopharmaceuticals used in nuclear medicine, exploit special pathophysiologic localization mechanisms and provide unique functional information for their target tissues. Thus, many of the above mentioned problems can be elucidated. This is obvious in the published figures of sensitivity and specificity of the radionuclidic methods, which are often superior to those of CT [Table 1: see text]. In this article the main nuclear medicine procedures in the field of lung cancer imaging are reviewed. Emphasis is given in newer developments such as (99m)Tc-sestamibi, labeled somatostatin analogues and positron emission tomography with (18)F-FDG. We especially describe the "weaknesses" of the anatomic-radiologic imaging modalities and how the attending physicians, i.e. the pneumonologists, oncologists and thoracic surgeons can overcome them, by using the functional imaging methods of nuclear medicine.
 ...
PMID:[Nuclear medicine procedures in lung cancer imaging]. 1584 Dec 89

Accurate evaluation of disease extent is mandatory when the diagnosis of resectable lung cancer is established. Staging has a significant impact on subsequent therapeutic options and prognosis. Radiologists can now rely on numerous instruments, each with different advantages and limitations. The procedure of choice is still chest X-ray whose intrinsic limitations require better tumor characterization with chest CT. CT difficulties in the differential diagnosis between the tumor and secondary changes occurring in adjacent structures can be overcome by 18F-FDG-PET or MRI. Functional information is acquired with the former and multiparametric information with the latter. According to the case, further extension to adjacent structures can be evaluated based on CT or MRI. For lymph node and distant metastasis PET is increasingly used, except for brain parenchyma where MRI is definitely more accurate in the detection of brain metastasis.
 ...
PMID:Noninvasive staging of lung cancer. 1585 21

We present a case of lung cancer that showed false positive accumulation in an 18F fluorodeoxyglucose positron emission tomography (FDG-PET) scan following induction chemotherapy for suspected metastasis and progression of malignancy. A 66-year-old man was diagnosed with squamous cell carcinoma in the lung, classified as clinical stage IIIA (T2N2M0), and underwent induction chemotherapy. An FDG-PET scan prior to chemotherapy demonstrated accumulation only in the tumor, whereas following treatment it revealed a strong accumulation not only in the tumor, but also in the supraclavicular lymph nodes, which indicated lymph node metastasis. The patient underwent a biopsy of the right supraclavicular lymph node and mediastinoscopy, after which all dissected lymph nodes showed sarcoid reactions and no tumor cells were found pathologically. We concluded that when evaluating the effect of induction chemotherapy for malignancy, a sarcoid reaction might lead to the false positive accumulation of FDG.
 ...
PMID:False positive accumulation in 18F fluorodeoxyglucose positron emission tomography scan due to sarcoid reaction following induction chemotherapy for lung cancer. 1587 53

Diagnostic imaging plays an important role in the monitoring of tumor response during lung cancer restaging to evaluate the efficacy of chemotherapy and/or radiation therapy during treatment, and in the detection of recurrent or metastatic neoplasm after treatment has been completed. While CT represents the primary imaging modality for lesion evaluation during restaging and for surveillance imaging once therapy has been completed, studies evaluating the role of 18-fluoro-2 deoxyglucose positron emission tomography (FDG-PET) in lung cancer restaging have shown promise regarding the detection of residual and recurrent neoplasm, and in evaluating for early response to first line therapy. With both CT and FDG-PET, residual or recurrent disease should, when possible, be differentiated from therapy-related changes in the lungs. We review the role of imaging in lung cancer restaging with attention to CT and FDG-PET for treatment assessment and the detection of recurrent or metastatic disease.
 ...
PMID:Imaging for lung cancer restaging. 1589 14

PET has seen rapid progression in recent years, with applications in oncology leading the way. The glucose analog (18)F-FDG is the most commonly used PET radiopharmaceutical and has been shown to accumulate avidly in several different neoplasms, including cancers of the lung. The following discussion will review the physiologic basis for the uptake of (18)F-FDG in lung neoplasms and demonstrate the utility of (18)F-FDG PET in lung cancer. A brief review of other PET radiopharmaceuticals in lung cancer imaging, and dual-modality PET/CT scanners, will be presented. Upon completion of this article, the reader should be able to describe the pharmacokinetics of (18)F-FDG and discuss the efficacy of (18)F-FDG PET scans in the evaluation of solitary pulmonary nodules, disease staging, and monitoring response to therapy. Additionally, the reader should be able to compare (18)F-FDG PET with conventional anatomic imaging and describe some of the technical challenges of PET/CT fusion imaging.
 ...
PMID:Utility of 18F-FDG PET in evaluating cancers of lung. 1593 19


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>